Please select how you are accessing this portal. You will need an invitation code for either path.
All materials are confidential. Questions? invest@inpursuithealth.com
This portal contains confidential investment materials distributed by invitation only. You must have received an access code to proceed.
All materials are confidential and subject to NDA. Questions? invest@inpursuithealth.com
Please introduce yourself. Your information is kept strictly confidential and used only to facilitate your investor review.
Your information is never shared or sold.
Before proceeding, you must review the required disclosures for this offering. Please read the document below or download the full PDF.
This offering memorandum provides information about an offer to sell securities of InPursuit Health, LLC to a limited number of accredited investors, in a manner defined by Regulation D promulgated by the SEC. The Company in its sole discretion may accept or reject any subscription, in whole or in part, at any time prior to completion of this offering.
This memorandum is submitted on a confidential basis solely for consideration of the securities described herein in a private placement. The acceptance of this memorandum constitutes an agreement to maintain strict confidentiality of all information contained herein. This memorandum may not be reproduced in whole or in part, and its use for any purpose other than an investment in the described securities is not authorized and is prohibited.
The offered securities have not been registered under the Securities Act of 1933 or any state securities laws. This offering is made in reliance upon an exemption from registration pursuant to Rule 506(b) of Regulation D. The securities are restricted and may not be transferred without an effective registration statement or an opinion of counsel acceptable to the Company.
Investment in a small business involves a high degree of risk. Investors should not invest any funds in this offering unless they can afford to lose their entire investment. Key risks include: early-stage development with no assurance of profitability; risk of total loss; dependence on key personnel; need for additional financing; extensive government regulation including HIPAA; reimbursement uncertainty; illiquidity of the investment; and no public market for the securities.
The securities are suitable only for long-term investment by persons who have sufficient financial means to bear the risk of total loss and who have no need for liquidity. Each investor must qualify as an Accredited Investor as defined under Rule 501(a) of Regulation D, and must have the financial ability to bear the economic risks of the entire investment for an indefinite period.
Certain information constitutes forward-looking statements. Due to various risks and uncertainties, actual events or results may differ materially from those reflected in such statements. The information contained in this memorandum has been compiled by the Company as of March 1, 2026.
Confidential · For Accredited Investors Only
You must certify your accredited investor status before accessing confidential offering materials. Please read carefully before proceeding.
The materials in this data room constitute confidential information pertaining to a private securities offering by InPursuit Health, LLC, a Wyoming limited liability company. Access is restricted to Accredited Investors as defined under Rule 501 of Regulation D under the Securities Act of 1933, as amended.
These materials are provided for informational purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security. Any such offer will be made only through definitive offering documents delivered to qualified investors.
Investing in early-stage companies involves a high degree of risk, including the possibility of total loss. Past performance at DoD/VA scale is not indicative of future results. Forward-looking statements are subject to material risks and uncertainties.
These materials are strictly confidential. Unauthorized distribution or disclosure is prohibited. By accessing this data room you agree to maintain strict confidentiality. These materials have not been reviewed or approved by the SEC or any state regulator.
Confidential · For Accredited Investors Only
Before accessing these materials, please confirm your understanding of their confidential nature and your role as an advocate.
The materials in this portal have been shared with you as an advocate, advisor, or strategic partner of InPursuit Health, LLC. These materials are provided for informational and relationship purposes only.
These materials do not constitute an offer to sell or solicitation of an offer to buy any security. Access as an advocate does not establish any investor relationship with InPursuit Health.
All materials you access are strictly confidential. You agree not to reproduce, distribute, or disclose any content to any third party without the prior written consent of InPursuit Health, LLC.
Unauthorized distribution of these materials is prohibited and may result in legal liability.
Confidential · Advocate Access
InPursuit Health is raising $3.5M in seed funding through a single round of new Class C units at a $20M pre-money valuation. Priced equity, $25K minimum, one close.
Year 3 base case: $35M revenue at 25 enrolled members — just 25 of the 230,000+ physician practices across the country, with Honeycomb Medical Group already signed as our first. Request materials at invest@inpursuithealth.com.
Every milestone is complete. The platform is built, CMS-cleared, and commercially ready. Partners are delivering. The only thing standing between today and launch is capital.
Product, regulatory, infrastructure, and commercialization are done. Two partnerships are in-flight and progressing on schedule. The single remaining dependency is the $3.5M Class C close — capital to execute the launch.
Most startups raise capital to build the product. InPursuit raised capital to launch a finished one. This is the only dependency between today and launch. Every other milestone — product, regulatory, infrastructure, partnerships, commercialization — is complete or progressing on schedule. Capital converts readiness into revenue.
Initiative
Initiative
Initiative
Initiative
